Sector Insights — 5 June 2026
Inside Phase II: building biosimilar, oncology and vaccine capability in Egypt
Sixty thousand square metres of the Gypto complex are dedicated to specialised high-technology therapies. Here is why that footprint matters more than its size suggests.
Of the 180,000 square metres that make up the Gypto pharmaceutical complex, 120,000 are dedicated to essential medicines. The remaining 60,000 are reserved for something considerably harder: specialised and high-technology therapies.
Biosimilars, oncology products and vaccines sit at the top of the pharmaceutical complexity curve. They demand biological process capability, cold-chain integrity, analytical characterisation and regulatory dossiers that take years to assemble. Very few facilities in the region can host all three.
Phase II is being built around exactly that capability, supported by technology transfer arrangements — insulin with Gan & Lee, vaccines with Bio E — that shorten the path from empty clean room to approved product.
The strategic logic is regional rather than national. A facility able to produce biosimilars and vaccines at scale in Egypt reduces the Middle East's dependence on imported specialised therapies, and gives multinational originators a compliant manufacturing base inside the region they are selling into.
